Status:
COMPLETED
Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether a low dose and a high dose of the study drug SCA-136 are effective and safe in the treatment of schizophrenia requiring hospitalization.
Eligibility Criteria
Inclusion
- Clinical diagnosis of schizophrenia
- Ability to remain hospitalized for at least first 4 weeks of study
- Needs hospitalization due to worsening of schizophrenia
Exclusion
- Type 1 or 2 diabetes
- Previous use of clozapine
- Serious medical illness other than schizophrenia
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00265551
Start Date
January 1 2006
End Date
January 1 2007
Last Update
December 10 2007
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States, 72201
2
Cerritos, California, United States, 90703
3
Costa Mesa, California, United States, 92627
4
La Mesa, California, United States, 91942